NorthWest Biotherapeutics Inc (NWBO)

[investor_2013]

BMY didn't develop checkpoint inhibitors by itself. Rather, BMY obtained checkpoint inhibitors by acquiring Medarex in 2009. Celldex is spun out of Medarex in 2005. In fact, Celldex management including CEO came from Medarex. The 50 billion rise of BMY's market cap in recent years could be because of its checkpoint inhibitors. So even if not scientifically best choice, it's not surprising at all to see that BMY stretched out his hand to help those people who developed its successful checkpoint inhibitors. To BMY, even if it's a waste at the end, the cost of several hundred million is peanuts comparing to its current gain of $50 billion cap.